Evercore ISI analyst Daniel Markowitz had a “Tactical Outperform” call on West Pharmaceutical (WST) heading into earnings, but is removing it from the firm’s TAP list given that West reported earnings late last week. The firm has an Outperform rating and $390 price target on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target raised to $325 from $275 at Barclays
- West Pharmaceutical price target raised to $370 from $310 at BofA
- West Pharmaceutical price target raised to $355 from $320 at UBS
- West Pharmaceutical price target raised to $345 from $305 at Deutsche Bank
- West Pharmaceutical Services Reports Strong Q3 2025 Results